Table of Contents Author Guidelines Submit a Manuscript
Journal of Immunology Research
Volume 2019, Article ID 7239347, 14 pages
https://doi.org/10.1155/2019/7239347
Research Article

Cross-Reaction, Enhancement, and Neutralization Activity of Dengue Virus Antibodies against Zika Virus: A Study in the Mexican Population

1Departamento de Biomedicina Molecular, CINVESTAV IPN, Av. IPN # 2508 Col. San Pedro Zacatenco, Ciudad de México, Mexico
2Laboratorio Multidisciplinario en Ciencias Biomédicas, Instituto de Investigaciones Médico-Biológicas, Universidad Veracruzana, Veracruz, Mexico
3Unidad de Desarrollo e Investigación en Bioprocesos, Escuela Nacional de Ciencias Biológicas, Instituto Politécnico Nacional, Ciudad de México, Mexico
4Laboratorio Central de Epidemiología, Centro Médico Nacional La Raza, Instituto Mexicano del Seguro Social, Ciudad de México, Mexico
5Departamento de Inmunología, UMF Facultad de Estudios Superiores-Iztacala, Universidad Nacional Autónoma de México, Av. de los Barrios 1, Los Reyes Iztacala, Edo. de México, Tlalnepantla, Mexico
6Laboratorio Central de Epidemiología, Coordinación de Vigilancia Epidemiológica, Instituto Mexicano del Seguro Social, Ciudad de México, Mexico

Correspondence should be addressed to Leticia Cedillo-Barrón; xm.vatsevnic@ollidecl

Mayra R. Montecillo-Aguado and Alfredo E. Montes-Gómez contributed equally to this work.

Received 30 November 2018; Revised 15 May 2019; Accepted 8 July 2019; Published 2 September 2019

Academic Editor: Kurt Blaser

Copyright © 2019 Mayra R. Montecillo-Aguado et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Zika virus (ZIKV), an emerging mosquito-borne flavivirus, has quickly spread in many regions around the world where dengue virus (DENV) is endemic. This represents a major health concern, given the high homology between these two viruses, which can result in cross-reactivity. The aim of this study was to determine the cross-reacting antibody response of the IgM and IgG classes against the recombinant envelope protein of ZIKV (rE-ZIKV) in sera from patients with acute-phase infection of different clinical forms of dengue, i.e., dengue fever (DF) and dengue hemorrhagic fever (DHF) (before the arrival of ZIKV in Mexico 2010), as well as acute-phase sera of ZIKV patients, together with the implications in neutralization and antibody-dependent enhancement. Differences in IgM responses were observed in a number of DF and DHF patients whose sera cross-reacted with the rE-ZIK antigen, with 42% recognition between acute-phase DHF and ZIKV but 27% recognition between DF and ZIKV. Regarding IgG antibodies, 71.5% from the DF group showed cross-reactivity to rE-ZIKV in contrast with 50% and only 25% of DHF and ZIKV serum samples, respectively, which specifically recognized the homologous antigen. The DHF group showed more enhancement of ZIKV infection of FCRγ-expressing cells compared to the DF group. Furthermore, the DHF group also showed a higher cross-neutralizing ability than that of DF. This is the first report where DF and DHF serum samples were evaluated for cross-reactivity against Zika protein and ZIKV. Furthermore, DENV serum samples cross-protect against ZIKV through neutralizing antibodies but at the same time mediate antibody-dependent enhancement in the sequential ZIKV infection.